Navigation Links
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Date:6/22/2009

- FDA Agreement Reached on Phase 3 Study Design, Primary Endpoint and Histological Methodology -

CRANBURY, N.J., June 22 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the U.S. Food and Drug Administration (FDA) on the key protocol design elements of the pivotal trial, including the use of the surrogate primary endpoint of the change in the amount of kidney interstitial capillary GL-3, the substrate that accumulates in the cells of Fabry patients. In addition, the FDA is in agreement that the Company is eligible to seek Accelerated Approval for Amigal according to Subpart H regulations. The Company has begun submitting the Phase 3 protocol to investigational sites worldwide and expects to begin the dosing of subjects in the second half of this year.

John F. Crowley, President and CEO of Amicus stated, "The start of our Phase 3 trial with Amigal is a major milestone for Amicus and highlights our transition into a late-stage development company." Crowley continued, "We are very pleased with the outcome of our interactions with FDA around the design of this pivotal study and are confident we have set the stage for a successful Phase 3 study. We continue to believe that Amigal may be an important treatment option for patients who suffer with Fabry disease and a significant step forward for them and their families."

Raphael Schiffmann, MD, Director of the Institute of Metabolic Disease, Baylor Health Care System Foundation, commented, "Having been involved in Fabry research for more than 15 years and considering the Phase 2 data with migalastat, I am pleased that the Phase 3 trial is st
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  In Detroit, where three out ... rate is two and one half times of the national ... of 10 infants that die in Detroit ... statistics that Covenant Community Care, a faith-based, charitable non-profit Community ... to change thanks to a charitable donation by Konica Minolta ...
(Date:4/17/2015)... Apr. 17, 2015 Steven Rash , the ... and its operating subsidiary American Seed & Oil Company, ... to investors yesterday in New York City.  Mr. Rash,s ... The American Seed & Oil Company has recently announced ... Butter Hemp Seed Foods , the EpiVape , ...
(Date:4/17/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kh5kqg/the_corporate ) ... Corporate Reputation of Pharma - The Patient Perspective ... to their offering. The Corporate Reputation ... its fourth edition. This report contains the latest ... annual Corporate Reputation report, the author surveys a ...
Breaking Medicine Technology:Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 2Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 3Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 4American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2
... Biopure Corporation,(Nasdaq: BPUR ) announced today that ... a new protocol for review by the Food ... trial of Hemopure(R),[hemoglobin glutamer - 250 (bovine)], or ... hemorrhagic shock without,availability of blood transfusions. The proposed ...
... Leukemia & Lymphoma,Society (LLS) and Memgen jointly announced an ... trial. The trial will use Memgen,s,ISF35, an active immunotherapy ... its alliance with LLS, Memgen plans to begin a ... patients who have 17p-, refractory or,resistant CLL with limited ...
Cached Medicine Technology:U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R) 2U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R) 3The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial 2The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial 3
(Date:4/17/2015)... Bradley, Illinois (PRWEB) April 17, 2015 ... host a Party on the Patio from 2 p.m. ... which is located at 1320 Executive Ct. in Pekin, ... on Medicaid, who need some help to maintain their ... steel drums, and tropical treats will be served during ...
(Date:4/17/2015)... Oklahoma (PRWEB) April 17, 2015 Alcohol ... Drug Dependence (NCADD) notes that drinking and driving has ... At the same time, the link between alcohol ... as domestic abuse and violence and sexual assault, and ... According to the NCADD, 5.3 million adults in America ...
(Date:4/17/2015)... 17, 2015 In Defense of Christians ... statement: “On Wednesday April 15th, the European Parliament joined ... resolution recognizing the Armenian Genocide, “paying tribute, on the ... one-and-a-half million innocent Armenian victims who perished in the ... the EU for this timely and needed recognition of ...
(Date:4/17/2015)... 17, 2015 As a board-certified orthopedic ... new offering of platelet-rich plasma (PRP) and ... is known for its world-class care of injury-caused ... surgical experience lacking in many other physicians offering regenerative ... are utilized for pain management and rehabilitation. Dr. Meier ...
(Date:4/17/2015)... Fla. (PRWEB) April 17, 2015 Baptist ... Center have signed a partnership agreement designed to transform ... , The institutions have agreed to create a joint ... treatment protocols and translational research. Baptist MD Anderson Cancer ... 2015, providing a single destination for highly coordinated, multidisciplinary ...
Breaking Medicine News(10 mins):Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3
... few decades ago, sudden cardiac arrest was a death sentence. ... once every six hours in Sweden, reveals a thesis from ... all cases of sudden cardiac arrest over a 30-year period. ... treatment of victims of sudden cardiac arrest, shows a thesis ...
... -- Some patients with inflammatory bowel disease may be ... use of immunosuppressant drugs to treat the intestinal disorder, ... The studies, published in the November issue of the ... used to treat patients with irritable bowel disease, or ...
... School of Medicine in St. Louis have obtained new ... by mutations in a gene governing not speech, but ... Beyond a simple association, the study provides the ... lysosomes actually play a role in causing some people ...
... Alan Mozes HealthDay Reporter , TUESDAY, Nov. 22 ... of coffee may reduce their risk for endometrial cancer, new ... the largest study to date to explore the impact of ... is cancer that originates in the lining of the uterus. ...
... , TUESDAY, Nov. 22 (HealthDay News) -- ,A ... to turn off areas of the brain associated with daydreaming ... more about how meditation works could help advance research into ... Brewer, an assistant professor of psychiatry at Yale University. ...
... believed to be the first study of its kind ... without anxiety) and the amount of time to diagnostically ... Boston University School of Medicine (BUSM) have found suffering ... to diagnostic resolution in a vulnerable population of urban ...
Cached Medicine News:Health News:Sharp decrease in deaths from sudden cardiac arrest 2Health News:Chronic Bowel Disease Drugs Linked to Skin Cancer Risk 2Health News:Surprising pathway implicated in stuttering 2Health News:Surprising pathway implicated in stuttering 3Health News:Study Links Coffee to Lower Risk of Endometrial Cancer 2Health News:Study Links Coffee to Lower Risk of Endometrial Cancer 3Health News:Meditation Can 'Turn Off' Regions of the Brain 2Health News:Depression and anxiety not linked to delayed resolution of abnormal mammograms, Pap tests 2
... DRE-200 ESU units use dedicated digital hardware ... processing data. This hardware allows parallel data ... throughput, measuring tissue impedance 5000 times per ... digitally, being converted to analog only in ...
... Mitek is the Market leader in soft ... Suture, DePuy Mitek has developed the latest ... open shoulder repair. ORTHOCORD Suture is as ... the market. Most importantly, ORTHOCORD Suture handles ...
... surgical gloves were designed with the surgeon ... barrier protection, and value. It offers comfort ... and dry hands. The broader, anatomical design ... micro-rough surface offers sensitivity and an effective ...
The Next Generation in Operating Room Equipment and Management Solutions is here Today. NuBoom is a self-contained, pedestal-mounted boom that houses medical, audio and visual equipment....
Medicine Products: